Parexel expands Ph I research capabilities in China

"Parexel has seen a consistent increase in the number of Phase I studies both in healthy subjects and patients being conducted in China in recent years," said Gadi Saarony, Executive Vice President and Chief Clinical Research Services Officer.

Parexel, a leading provider of solutions to accelerate the development and delivery of innovative new therapies to improve world health, from Clinical through to Commercialization, announced it has formed alliances with three prominent healthcare institutions ─ PKUCare Luzhong Hospital, West China Medical Center, and Shanghai Xuhui Central Hospital ─ providing an enhanced level of support for customers conducting Phase I studies in China.

"While there is great opportunity in the region, many companies struggle with having the local infrastructure required to initiate Early Phase studies quickly and efficiently, which is critical to success in the long-term. Through these local partnerships, Parexel is able to provide on-the-ground support for rapid start-up and study execution, complementing our proven Early Phase Clinical Pharmacology expertise, along with project and data management and regulatory consulting capabilities with the aim of providing customers with proven strategies for success in China."

The alliances build on Parexel’s significant expertise in this region to provide global and local biopharmaceutical companies with:

• Practical research capabilities, experienced site Principal Investigators and guaranteed access to over 250 clinical research beds
• The ability to conduct rapid study start-up leveraging local resources
• A dedicated local Parexel Clinical Pharmacologist and Project Managers to streamline and simplify communications and processes
• Access to Parexel’s expertise to support local ethics applications and regulatory requirements
• Experienced Chinese Quantitative Clinical Development/Data Management/Biostatistics/Programming/Medical writing team to provide integrated early phase solutions.

Parexel recently was recognized as a leader in Phase I clinical development by Industry Standard Research in its 2019 CRO Quality Benchmarking Report. The company has eight offices and more than 1,700 employees across all functions in Greater China as well as more than 8,000 employees in the Asia/Pacific region.

The Early Phase alliances in China were formalized following the successful completion of several Phase I studies, and the establishment of collaboration agreements and operational systems between Parexel and the local institutions.

-----------------------------------------------------------------------
Editor's Note: For any copyright disputes involving the content,
please email: Julia.Zhang@ubmsinoexpo.com to delete.